Prescriptions for mesalazine and sulphasalazine: A prevalence estimate of patients treated for inflammatory bowel disease in Rome

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 4, 1996, Pages 659-663

  Tebano, M T ^a   Traversa, G ^a   Da Cas, R ^a   Loizzo, A ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MESALAZINE; SALAZOSULFAPYRIDINE;

ARTICLE; DRUG USE; ENTERITIS; HUMAN; ITALY; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0030035410     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.18160000.x     Document Type: Article

References (40)

1. Carpani de Kaski M, Hodgson HJF. Rolling review: inflammatory bowel diseases. Aliment Pharmacol Ther 1993; 7: 567-79.
2. Meyers S. Oral and parenteral corticoids. In: Peppercorn MA, ed. Therapy of Inflammatory Bowel Disease. New Medical and Surgical Approaches. New York: Marcel Dekker, 1990: 3-34.
3. Jarnerot G. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs 1989; 37: 73-86.
4. Hanauer SB. Topical and oral aminosalicylates. In: Peppercorn MA, ed. Therapy of Inflammatory Bowel Disease. New Medical and Surgical Approaches. New York: Marcel Dekker, 1990: 65-91.
5. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Gastroenterology 1993; 104: 1293-1301.
6. Goldstein F, Farquhar S, Thornton JJ, Abramson J. Favorable effects of sulphasalazine on small bowel Crohn's disease: a long-term study. Am J Gastroenterol 1987; 82: 848-55.
7. Summers RW, Switz DM, Session JT, Jr, et al. Results of drug treatment. Gastroenterology 1979; 77: 847-69.
8. Riis P, Anthonisen P, Wulff HR, et al. The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year. Scand J Gastroenterol 1973; 8: 71-4.
9. Dissanayake AS, Trulove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine. Gut 1973; 14: 925-6.
10. Evans JG, Achenson ED. An epidemiological study of ulcerative colitis and regional enteritis in the Oxford area. Gut 1965; 6: 311-24.
11. Monk M, Mendeloff AI, Siegel CI, Lilienfeld AM. An epidemiological study of ulcerative colitis and regional enteritis among adults in Baltimore. Hospital incidence and prevalence, 1960 to 1965. Gastroenterology 1967; 55: 198-210.
12. Garland CF, Lilienfeld AM, Mendeloff AI, et al. Incidence rate of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology 1981; 81: 1115-24.
13. Sonnenberg A. Hospital discharges for inflammatory bowel disease. Time trends from England and the United States. Dig Dis Sci 1990; 35: 375-81.
14. Maggini M, Menniti Ippolito F, Spila Alegiani S, Traversa G, Fortini M. Drug utilization studies within the VIDEOFAR project. Ann Ist Sup Sanità 1991; 27: 201-6.
15. Nordic Statistics in Medicine. Anatomical Therapeutic Chemical Classification. Uppsala: Nordic Council on Medicines, 1987.
16. Muss AA, Carbone JV, Kressell HY. Radiologic and clinical assessment of broad-spectrum antibiotic therapy in Crohn's disease. Am J Roentgenol 1978; 131: 787-90.
17. Barrett KE, Dharmathaption K. Pharmacological aspects of therapy in inflammatory bowel diseases: anti-diarrheal agents. J Clin Gastroenterol 1988; 10: 57-65.
18. Brandt LJ. Metronidazole. In: Peppercorn MA, ed. Therapy of Inflammatory Bowel Disease. New Medical and Surgical Approaches. New York: Marcel Dekker, 1990; 95-102.
19. Fleming CR. Enteral and parenteral nutrition. In: Peppercorn MA, ed. Therapy of Inflammatory Bowel Disease. New Medical and Surgical Approaches. New York: Marcel Dekker, 1990: 145-57.
20. Elsborg L, Larsen L. Folate deficiency in chronic inflammatory bowel diseases. Scand J Gastroenterol 1979; 14: 1019-24.
21. Thompson WG, Wrathell E. The relation between ileal resection and vitamin B12 absorption. Can J Surg 1977; 20: 461-9.
22. Keisu M, Ekman E. Sulphasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features, and estimation of its incidence. Eur J Clin Pharmacol 1992; 45: 215-8.
23. Devlin HB, Datta D, Dellipiani AW. The incidence and prevalence of inflammatory bowel disease in North Tees Health District. World J Surg 1980; 4: 185-95.
24. Binder V, Both H, Hansen PK, et al. Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen 1962-1978. Gastroenterology 1982; 83: 563-8.
25. Gollop JH, Phillips SF, Melton LJ III. Zinsmeister AR. Epidemiologic aspects of Crohn's disease: a population based study in Olmstead County, Minnesota, 1945-1982. Gut 1988; 29: 49-56.
26. Mayberry JF, Rhodes J. Epidemiological aspects of Crohn's disease: a review of the literature. Gut 1984; 20: 602-8.
27. Mayberry JF. Some aspects of the epidemiology of ulcerative colitis. Gut 1985; 26: 968-74.
28. Ruiz V. Crohn's disease in Galicia, Spain. Scand J Gastroenterol 1989; 24 (Suppl. 170): 29-31.
29. Vucelic B, Korac B, Sentic M, et al. A Epidemiology of Crohn's disease in Zagreb. Yugoslavia: A ten-year prospective study. Int J Epidemiol 1991; 20: 216-20.
30. Lanfranchi GA, Michelini A, Brignola C, et al. Uno studio epidemiologico sulle malattie infiammatorie intestinali nella provincia di Bologna. G Clin Med 1976; 57: 235-45.
31. Ekbom A, Helmick C, Zack M, Adami HO. The epidemiology of inflammatory bowel disease: a large, population based study in Sweden. Gastroenterology 1991; 100: 350-8.
32. Trallori G, D'Albasio G, Palli D, et al. Epidemiology of inflammatory bowel disease over a 10-year period in Florence (1978-1987). Ital J Gastroenterol 1991; 23: 559-63.
33. Cottone M, Cipolla C, Orlando A, et al. Hospital incidence of Crohn's disease in the province of Palermo. Scand J Gastroenterol 1989; 24 (Suppl. 170): 27-8.
34. Amanta E, Barbara L, Biasco C, et al. Incidence and prevalence of Inflammatory Bowel Disease in Bologna - risk factors. Scand J Gastroenterol 1989; 24 (Suppl. 170): 63.
35. Goodman MJ, Strickland RG, Kirsner JB. Inflammatory bowel disease and lymphocitic antibody in members of the American Gastroenterological Association. Gastroenterology 1979; 76: 1140.
36. Kyle J. Crohn's disease in the Northeastern and Northern Isle of Scotland: an epidemiological review. Gastroenterology 1992; 103: 392-9.
37. Mayberry JF, Ballantyne KC, Hardcastle JD, Maugham C, Pye G. Epidemiological study of asymptomatic inflammatory bowel disease: the identification of cases during a screening programme for colorectal cancer. Gut 1989; 30: 481-3.
38. Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M and the Italian IBD Study Group. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's Disease. Gastroenterology 1992; 103: 363-8.
39. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. Gastroenterology 1993; 104: 435-9.
40. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid: Asacol) for the prevention of post operative recurrence of Crohn's disease. Aliment Pharmacol Ther 1994; 8: 35-43.